Company: BGLC
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001477932-25-002725
Chunk: 983

Company: BioNexus Gene Lab Corp
Filing Date: 2025-04-15
Form: 10-K
Item: Item 6
Chunk 983
---
Trading of industrial chemicals    Year ended December 31, 2024  Year ended December 31, 2023               REVENUE  $16,069  $9,494,577  $24,219  $9,746,587                   COST OF REVENUE   (7,316)  (8,213,809)  (19,851)  (8,421,457)                  GROSS PROFIT   8,753   1,280,768   4,368   1,325,130                   OTHER INCOME                 Dividend income    -   68,130   -   61,409 Interest income   109,444   38,197   19,629   49,046 Fair value gain on investments in equity securities   -   69,476   - 306,614 Gain on disposal of investments in equity securities    -   38,409   -    7,245 Reversal of expected credit losses   -   1,689,412   -   - Others   13,507   45,898   -   42,093 TOTAL OTHER INCOME   122,951   1,949,522   19,629   466,407                   OPERATING EXPENSES                 Sales and marketing   (125,299)  (1,861,456)  (18,884)  (569,896)Research and development   (47,511)  -   (54,982)  - General and administrative   (194,038)  (679,321)  (171,881)  (134,678)Provision for expected credit losses    -   (883,533)  -   (1,314,427)TOTAL OPERATING EXPENSES   (366,848)  (3,424,310)  (245,747)  (2,019,001)                  LOSS FROM OPERATIONS   (235,144)  (194,020)  (221,750)  (227,464)